Every pneumonia vaccine currently licensed and in clinical use relies on older technology, not mRNA. The vaccines you receive at a pharmacy or doctor’s office to protect against pneumococcal disease are conjugate vaccines or polysaccharide vaccines, both of which deliver pieces of the bacterium’s sugar coating directly to your immune system. This stands in sharp contrast to the mRNA approach made famous by COVID-19 shots, and the reasons for the difference run deeper than most people realize.
What Today’s Pneumonia Vaccines Actually Contain
When people say “the pneumonia vaccine,” they almost always mean a vaccine against Streptococcus pneumoniae, the bacterium historically responsible for more cases of community-acquired pneumonia than any other single pathogen.1PubMed Central. Etiology of community-acquired pneumonia in adults: a systematic review The vaccines targeting this bacterium come in two basic forms. Polysaccharide vaccines, like PPSV23, contain purified sugar molecules taken from the outer capsule of 23 different pneumococcal strains. Conjugate vaccines, like PCV15, PCV20, and the newer PCV21, take those capsular sugars and chemically link them to a carrier protein. That linkage was a breakthrough: pure polysaccharide vaccines failed to protect infants and toddlers, who faced the highest risk of pneumococcal disease, because very young immune systems do not respond well to sugar molecules alone.2PubMed Central. The remarkable history of pneumococcal vaccination: an ongoing challenge
Conjugating the polysaccharide to a protein transforms the immune response. The resulting molecule triggers a more complete reaction, including the production of high levels of protective antibodies, the creation of immune memory cells, and the ability to mount a fast, strong response if you encounter the bacterium later. Clinical studies have confirmed that these conjugate vaccines generate functionally active antibodies even in young children, and a booster dose later in life produces a rapid recall response.3PubMed. Immunogenicity of pneumococcal conjugate vaccines None of this involves mRNA, lipid nanoparticles, or instructing your cells to manufacture a protein. The immune-stimulating ingredients are delivered ready-made.
Why mRNA Has Not Replaced Conjugate Technology for Pneumonia
The mRNA vaccines developed for COVID-19 work by delivering a genetic instruction set, wrapped in a tiny fat bubble called a lipid nanoparticle, into your cells. Once inside, the mRNA tells your cells to build a specific viral protein, which the immune system then recognizes as foreign and mounts a defense against.4Nature Reviews Materials. Lipid nanoparticles for mRNA delivery This works elegantly for viruses, because the targets your immune system needs to learn (like the spike protein of SARS-CoV-2) are proteins, and mRNA is a natural blueprint for proteins.
Pneumococcal vaccines, however, target something fundamentally different: polysaccharides. These are complex sugar chains, not proteins, and mRNA simply cannot encode them. Sugar molecules are assembled by enzymes through metabolic pathways, not translated from a genetic template the way proteins are. A recent analysis in The Lancet Microbe put it plainly: mRNA cannot encode polysaccharide antigens, and for key bacterial pathogens like S. pneumoniae, the dominant protective targets include capsular polysaccharide conjugates.5International Journal of Infectious Diseases. mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies This is not a temporary engineering hurdle that will be solved with better lipid nanoparticles or improved mRNA sequences. It is a basic incompatibility between the technology and the target.
There is a second, subtler problem. Even when researchers try to use mRNA to encode bacterial protein antigens instead of polysaccharides, the proteins get made inside mammalian cells. Bacterial proteins produced in human cells may fold differently or carry different chemical decorations than they would on the surface of a living bacterium. That mismatch could change how the immune system recognizes the target, potentially weakening the protection.5International Journal of Infectious Diseases. mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies
The Current Vaccine Landscape and Who Should Get What
The Advisory Committee on Immunization Practices (ACIP) in the United States currently recommends pneumococcal conjugate vaccines for two main groups: adults aged 19 and older who have certain risk conditions (chronic heart or lung disease, diabetes, immunocompromising conditions, smoking, and others), and all adults aged 50 and older regardless of risk factors. The recommendation for the broader 50-and-up group was expanded in late 2024.6MMWR Morbidity and Mortality Weekly Report. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years
Several conjugate vaccine products are now available. PCV15 covers 15 serotypes, PCV20 covers 20, and PCV21 was recommended by ACIP as an option for adults who are due for a pneumococcal conjugate dose.7Morbidity and Mortality Weekly Report. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults The newest of these, PCV21, covers eight serotypes not found in earlier conjugate vaccines, and a Canadian study found it provided significantly greater coverage than PCV15, PCV20, or the older polysaccharide vaccine PPSV23 across all adult age groups and geographic regions studied, including against multidrug-resistant strains.8PubMed Central. Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116) This ongoing expansion of serotype coverage illustrates why conjugate technology remains the active frontier for pneumococcal prevention: the challenge is covering more of the roughly 100 known pneumococcal serotypes, not switching to a new platform.
What About Pneumonia Caused by Viruses?
Here is where things get a bit more interesting. Pneumonia is not a single disease caused by a single germ. It is a condition — infected, inflamed lungs — that can be caused by bacteria, viruses, fungi, or combinations of these. A large U.S. study of hospitalized adults with community-acquired pneumonia found that a pathogen was identified in about 38% of cases. Among those, viruses alone accounted for roughly 23%, bacteria for about 11%, and mixed bacterial-viral infections for around 3%. The most commonly detected pathogens were rhinovirus and influenza, with S. pneumoniae coming in third.9PubMed Central. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
Another retrospective study found that about a fifth of community-acquired pneumonia cases were caused by viral pathogens, with an additional 13.5% involving bacterial-viral coinfection.10International Journal of Infectious Diseases. Comparing viral, bacterial, and coinfections in community-acquired pneumonia So when we talk about “the pneumonia vaccine,” we are really talking about vaccines against the bacterial cause, primarily pneumococcus. The viral causes of pneumonia — influenza, RSV, SARS-CoV-2 — are addressed by separate vaccines, some of which do use mRNA technology. If you have received an mRNA COVID-19 vaccine, that shot does offer some indirect protection against one viral cause of pneumonia, but it is not what anyone means by “the pneumonia vaccine.”
Early mRNA Research Against Pneumococcus
The polysaccharide barrier has not stopped researchers from exploring whether mRNA might work against pneumococcus through a different angle. Instead of targeting the sugar capsule, some teams are designing mRNA vaccines that encode conserved protein antigens found across many pneumococcal serotypes. One recent study used computational approaches to design a multi-epitope mRNA vaccine candidate against S. pneumoniae that targets shared protein fragments rather than serotype-specific polysaccharides. The researchers described it as a promising serotype-independent candidate, but it remains entirely in the computer-modeling stage and has not been tested in animals or humans.11Scientific Reports. In silico design and characterization of a novel multi-epitope mRNA vaccine candidate against Streptococcus pneumoniae
The appeal is obvious. If you could target proteins shared by all pneumococcal strains, you might not need to keep adding serotypes to conjugate vaccines every few years. But the science is genuinely early. No mRNA pneumococcal vaccine has entered clinical trials, and the question of whether protein-based targets can match the protection provided by polysaccharide-targeting conjugate vaccines is unanswered. Conjugate vaccines have decades of real-world effectiveness data; any mRNA alternative would need to demonstrate comparable or superior protection in head-to-head studies that are years away at minimum.
How mRNA and Conjugate Vaccines Differ in Side Effects
People who received mRNA COVID-19 vaccines often experienced noticeable short-term side effects: sore arms, fatigue, fever, body aches. This has led some to wonder whether pneumonia vaccines are similarly reactive. The side-effect profiles are actually somewhat different. A systematic review of pneumococcal conjugate vaccine safety found that while conjugate shots can cause more local reactions and low-grade fever than some other childhood vaccines, the reactions were mild and self-limited. The vaccines did not carry an increased risk of severe injection-site reactions or high fever.12PubMed Central. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data
A phase 3 trial comparing the 15-valent conjugate vaccine (V114) to PCV13 in adults aged 50 and older found that the most commonly reported side effects across both groups were injection-site pain, fatigue, and muscle aches, consistent with the known safety profile of conjugate vaccines in adults.13Vaccine. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine These are the same types of side effects you hear about with mRNA vaccines, but the underlying inflammatory response differs. Research comparing immune profiles between mRNA vaccine recipients and those receiving conventional vaccines found that mRNA recipients showed elevated levels of certain inflammatory blood proteins and more pronounced acute-phase responses, along with variability in antibodies against polyethylene glycol, a component of lipid nanoparticles.14PubMed Central. Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production In practical terms, both types of vaccine are considered safe, but the short-term inflammatory kick from mRNA vaccines tends to be more intense than what conjugate vaccines produce.
Combination mRNA Vaccines for Respiratory Infections
While mRNA is unlikely to displace conjugate technology for pneumococcal prevention any time soon, it is becoming an increasingly important platform for the viral pathogens that also cause pneumonia. Several research teams are developing combination mRNA vaccines that target multiple respiratory viruses in a single shot. One group designed an 8-valent mRNA vaccine encoding antigens from four seasonal influenza strains, three SARS-CoV-2 variants, and RSV simultaneously.15PubMed Central. Combination mRNA Vaccine Adjuvanted with CpG Oligodeoxynucleotides Enhances Protection against Respiratory Virus Infection Broader development of combination mRNA vaccines aiming to protect against multiple respiratory viruses with a single administration is underway.16PubMed Central. Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges
If these combination vaccines reach the market, you could eventually get a single mRNA shot covering influenza, COVID-19, and RSV in one visit, then separately receive your conjugate pneumococcal vaccine. That two-pronged approach — mRNA for the viral causes, conjugate for the bacterial cause — may end up being the practical future of pneumonia prevention. The technologies are complementary, not competitive. Each does something the other cannot.
Practical Storage and Access Differences
One comparison worth noting for anyone involved in distributing or recommending these vaccines: mRNA vaccines and conjugate vaccines have very different logistics. mRNA vaccines require cold-chain storage, with some needing ultra-cold freezers during distribution. Conjugate pneumococcal vaccines, by contrast, are stored under standard refrigeration, the same conditions used for most routine vaccines. A review of comparative strategies against pneumonia noted that while mRNA vaccines may offer higher immunogenicity for certain targets, they come with more demanding storage requirements, whereas older platforms like conjugate and even DNA vaccines are more stable and cost-effective to distribute.17The Open Microbiology Journal. A Review of Comparative Strategies Against Pneumonia: Vaccine and Antibiotic Resistance Mitigation In lower-resource settings where cold-chain infrastructure is limited, this difference is not trivial. It is one more reason conjugate vaccines remain the workhorse platform for pneumococcal disease globally.
Why People Confuse the Two
The confusion is understandable. The COVID-19 pandemic put mRNA vaccines into the spotlight so dramatically that many people now associate the word “vaccine” with mRNA by default. If you were told to “get your pneumonia vaccine” sometime after 2021, you might reasonably assume it uses the same technology as the COVID shots you had been hearing about. Adding to the confusion, you might receive both a pneumococcal conjugate vaccine and an mRNA COVID-19 booster in the same visit, reinforcing the mental link between the two.
But the pneumococcal vaccines on pharmacy shelves today — PCV15, PCV20, PCV21, and PPSV23 — are built on technology that predates the mRNA era by decades. The first pneumococcal conjugate vaccine (PCV7) was licensed in 2000, and the conjugation concept behind it had been under development since the 1980s. These vaccines have been refined by adding more serotypes over time, not by switching to a new platform. When your pharmacist gives you a pneumonia shot, you are receiving purified bacterial sugars attached to a carrier protein, not a genetic instruction set wrapped in a lipid bubble. The two technologies share a goal — training your immune system — but they accomplish it through fundamentally different mechanisms, and for pneumococcal disease specifically, the conjugate approach remains the only proven option available.